As
filed with the Securities and Exchange Commission on November 13, 2023
Registration
No. 333-
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
S-8
REGISTRATION
STATEMENT UNDER
THE
SECURITIES ACT OF 1933
Lineage
Cell Therapeutics, Inc.
(Exact
name of Registrant as specified in its charter)
California
(State
or other jurisdiction of
incorporation
or organization) |
|
94-3127919
(I.R.S.
employer
identification
number) |
|
|
|
2173
Salk Avenue, Suite 200, Carlsbad, CA
(Address
of principal executive offices) |
|
92008
(Zip
Code) |
Lineage
Cell Therapeutics, Inc. 2021 Equity Incentive Plan
(Full
title of the plan)
George
A. Samuel III
General
Counsel and Secretary
Lineage
Cell Therapeutics, Inc.
2173
Salk Avenue, Suite 200 Carlsbad, CA 92008
(Name
and address of agent for service)
(442)
287-8990
(Telephone
number, including area code, of agent for service)
Indicate
by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large
accelerated filer |
☐ |
Accelerated
filer |
☐ |
|
|
|
|
Non-accelerated
filer |
☒ |
Smaller
reporting company |
☒ |
|
|
|
|
|
|
Emerging
growth company |
☐ |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY
NOTE
This
Registration Statement on Form S-8 is being filed by Lineage Cell Therapeutics, Inc. (“Lineage”), with the U.S. Securities
and Exchange Commission (the “Commission”) for the purpose of registering an additional 19,500,000 common shares that may
be issued under the Lineage 2021 Equity Incentive Plan (the “2021 Plan”). At Lineage’s annual meeting of shareholders
held on September 6, 2023, Lineage’s shareholders approved an amendment to the 2021 Plan to increase the number of common shares
reserved for issuance of awards made thereunder by a total of 19,500,000.
Lineage
previously filed a Registration Statement on Form S-8 with the Commission on September 28, 2021 (File No. 333-259853) (the “Prior
Registration Statement”) to register an aggregate of 30,358,599 common shares available for issuance under the 2021 Plan, consisting
of, at a maximum, the sum of (i) 15,000,000 shares and (ii) an estimated 15,358,599 Prior Plan Returning Shares (as defined in the 2021
Plan). This Registration Statement registers an additional 19,500,000 common shares for issuance under the 2021 Plan, thereby increasing
the total number of common shares available for issuance under the 2021 Plan to an amount not to exceed the sum of (i) 34,500,000 shares
and (ii) the Prior Plan Returning Shares, if any, as such shares become available from time to time.
This
Registration Statement relates to securities of the same class as those registered under the Prior Registration Statement and is being
filed in accordance with General Instruction E to Form S-8. Pursuant to such instruction, the contents of the Prior Registration Statement
related to the 2021 Plan are hereby incorporated by reference in and made part of this Registration Statement, except to the extent supplemented,
superseded or modified by the specific information set forth below and/or the specific exhibits attached under Item 8 hereto, pursuant
to Rule 412 under the Securities Act of 1933, as amended (the “Securities Act”).
In
accordance with the instructional Note to Part I of Form S-8, the information specified by Part I of Form S-8 has been omitted from this
Registration Statement for offers of common shares pursuant to the 2021 Plan. The documents containing the information specified in Part
I will be delivered to the participants in the 2021 Plan as required by Rule 428(b)(1) under the Securities Act.
PART
II
INFORMATION
REQUIRED IN THE REGISTRATION STATEMENT
The
following exhibits are filed as a part of or incorporated by reference into this Registration Statement:
|
|
|
|
Incorporated
by Reference |
|
|
Exhibit No. |
|
Exhibit
Description |
|
Form |
|
File
No. |
|
Exhibit |
|
Filing
Date |
|
Filed
Herewith |
5.1 |
Opinion of Sheppard, Mullin, Richter & Hampton, LLP |
|
|
|
|
X |
23.1 |
Consent of WithumSmith+Brown, PC |
|
|
|
|
X |
23.2 |
Consent of Sheppard, Mullin, Richter & Hampton, LLP (included in Exhibit 5.1) |
|
|
|
|
X |
24.1 |
Power of Attorney (contained on the signature page of this Registration Statement) |
|
|
|
|
X |
99.1
|
Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan |
8-K |
001-12830-211254211 |
10.1 |
09/15/2021 |
|
99.2
|
Amendment to the Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan |
8-K |
001-12830-231242967 |
10.1 |
09/06/2023 |
|
99.3
|
Form of Stock Option Grant Notice and Agreement for Employees and Consultants under the Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan |
10-Q |
001-12830-211396840 |
10.4 |
11/10/2021 |
|
99.4
|
Form of Stock Option Grant Notice and Agreement for Non-Employee Directors under the Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan |
10-Q |
001-12830-211396840 |
10.5 |
11/10/2021 |
|
99.5 |
Form of Restricted Stock Unit Award Grant Notice and Agreement under the Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan |
10-Q |
001-12830-211396840 |
10.6 |
11/10/2021 |
|
107.1 |
Filing Fee Table |
|
|
|
|
X |
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Carlsbad, State of California, on November 13, 2023.
|
LINEAGE CELL THERAPEUTICS, INC. |
|
|
|
|
By: |
/s/
Brian M Culley |
|
Name: |
Brian
M Culley |
|
Title: |
Chief
Executive Officer |
KNOW
ALL MEN BY THESE PRESENTS, that each of the undersigned officers and directors of Lineage Cell Therapeutics, Inc., constitutes and appoints
Brian M. Culley and Jill Ann Howe, and each of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution,
for him or her and on his or her behalf and in his or her name, place and stead, in any and all capacities, to sign, execute and file
this Registration Statement under the Securities Act of 1933, as amended, and any one or more amendments to any part of this Registration
Statement, including any post- effective amendments, or appendices or supplements that may be required to be filed under the Securities
Act of 1933, as amended, to keep such Registration Statement effective or to terminate its effectiveness, with all exhibits and any and
all documents required to be filed with respect thereto, with the Securities and Exchange Commission or any regulatory authority, granting
unto such attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary
to be done in and about the premises in order to effectuate the same, as fully to all intents and purposes as he or she himself or herself
might or could do, if personally present, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute
or substitutes, may lawfully do or cause to be done.
Pursuant
to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities
and on the dates indicated.
Signature |
|
Title |
|
Date |
|
|
|
/s/
Brian M. Culley |
|
Chief
Executive Officer and Director |
|
November
13, 2023 |
Brian
M. Culley |
|
(Principal
Executive Officer) |
|
|
|
|
|
/s/
Jill Ann Howe |
|
Chief
Financial Officer |
|
November
13, 2023 |
Jill
Ann Howe |
|
(Principal
Financial and Accounting Officer) |
|
|
|
|
|
/s/
Alfred D. Kingsley |
|
Chair
of the Board |
|
November
13, 2023 |
Alfred
D. Kingsley |
|
|
|
|
|
|
|
/s/
Dipti Amin |
|
Director |
|
November
13, 2023 |
Dipti
Amin |
|
|
|
|
|
|
|
/s/
Deborah Andrews |
|
Director |
|
November
13, 2023 |
Deborah
Andrews |
|
|
|
|
|
|
|
|
|
/s/
Don M. Bailey |
|
Director |
|
November
13, 2023 |
Don
M. Bailey |
|
|
|
|
|
|
|
/s/
Neal C. Bradsher |
|
Director |
|
November
13, 2023 |
Neal
C. Bradsher |
|
|
|
|
|
|
|
|
|
/s/
Anula Jayasuriya |
|
Director |
|
November
13, 2023 |
Anula
Jayasuriya |
|
|
|
|
|
|
|
/s/
Michael H. Mulroy |
|
Director |
|
November
13, 2023 |
Michael
H. Mulroy |
|
|
|
|
|
|
|
/s/
Angus C. Russell |
|
Director |
|
November
13, 2023 |
Angus
C. Russell |
|
|
|
|
Exhibit
5.1
|
Sheppard,
Mullin, Richter & Hampton LLP
12275
El Camino Real, Suite 100
San
Diego, CA 92130
www.sheppardmullin.com |
November
13, 2023
VIA
E-MAIL
Lineage
Cell Therapeutics, Inc.
Attn:
Board of Directors
2173
Salk Avenue, Suite 200
Carlsbad,
CA 92008
Re:
Registration Statement on Form S-8
Ladies
and Gentlemen:
You
have requested our opinion with respect to certain matters in connection with the filing by Lineage Cell Therapeutics, Inc., a California
corporation (the “Company”), of a Registration Statement on Form S-8 (the “Registration Statement”) under the
Securities Act of 1933, as amended (the “Securities Act”), with the Securities and Exchange Commission (the “SEC”),
registering 19,500,000 common shares of the Company (the “Shares”) that may be issued from time to time under the Lineage
Cell Therapeutics, Inc. 2021 Equity Incentive Plan (as amended to date, the “Plan”).
This
opinion is being furnished in accordance with the requirements of Item 8 of Form S-8 and Item 601(b)(5)(i) of Regulation S-K.
In
connection with this opinion, we have reviewed and relied upon the Registration Statement, the Company’s restated articles of incorporation,
as amended and in effect as of the date hereof (the “Articles of Incorporation”), the Company’s amended and restated
bylaws as in effect on the date hereof (the “Bylaws” and together with the Articles of Incorporation, the “Charter
Documents”), the proceedings taken by the Company with respect to the authorization and adoption of the Plan, resolutions adopted
by the board of directors of the Company, and such other documents, records, certificates, memoranda and other instruments as we deem
necessary as a basis for this opinion. With respect to the foregoing documents, we have assumed (a) the genuineness of all signatures,
(b) the authenticity of all documents submitted to us as originals and (c) the conformity to originals of all documents submitted to
us as certified or reproduced copies. We have further assumed that (i) the common shares currently reserved for issuance under the Plan
will remain available for the issuance of the Shares, and (ii) neither the Charter Documents nor any of the proceedings relating to either
the Plan or any of the award agreements relating to the Shares will be rescinded, amended or otherwise modified prior to the issuance
of the Shares. We have also obtained from public officials and officers of the Company certificates or comparable documents as to certain
factual matters and, insofar as this opinion is based on matters of fact, we have relied on such certificates and comparable documents
without independent investigation.
On
the basis of the foregoing examination and in reliance thereon, subject to the further provisions hereof, we are of the opinion that
if, as and when the Shares are issued and sold by the Company in accordance with the terms of the award agreements provided for under
the Plan, and payment in full of the consideration therefor is received by the Company, the Shares will be validly issued, fully paid
and nonassessable.
We
consent to the filing of this opinion letter as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit
that we are included in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations
of the SEC promulgated thereunder.
The
foregoing opinion is limited to matters governed by the federal laws of the United States of America and the California General Corporation
Law.
This
opinion letter is rendered as of the date first written above solely for use in connection with the offer and sale of the Shares while
the Registration Statement is in effect, and is not to be relied upon for any other purpose. We disclaim any obligation to advise you
of facts, circumstances, events or developments which hereafter may be brought to our attention and which may alter, affect or modify
the opinion expressed herein. Our opinion is expressly limited to the matters set forth above, and we render no opinion, whether by implication
or otherwise, as to any other matters relating to the Company, the Shares, the Plan, the award agreements related to the Shares or the
Registration Statement.
|
Respectfully, |
|
|
|
/s/
Sheppard, Mullin, Richter & Hampton LLP |
|
|
|
SHEPPARD,
MULLIN, RICHTER & HAMPTON LLP |
Exhibit
23.1
CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We
hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated March 9, 2023, relating
to the consolidated financial statements of Lineage Cell Therapeutics, Inc. appearing in the entity’s Annual Report on Form 10-K
for the year ended December 31, 2022.
/s/
WithumSmith+Brown, PC
San
Francisco, California
November
13, 2023
Exhibit
107.1
Calculation
of Filing Fee Table
Form
S-8
(Form
Type)
Lineage
Cell Therapeutics, Inc.
(Exact
Name of Registrant as Specified in its Charter)
Table
1: Newly Registered Securities
Security
type | |
Security
class
title | |
Fee
calculation
rule | |
Amount
registered (1) | | |
Proposed
maximum
offering
price per
unit (2) | | |
Maximum
aggregate
offering
price | | |
Fee
rate | | |
Amount
of
registration
fee | |
Equity | |
Common Shares | |
Other | |
| 19,500,000 | | |
$ | 1.06 | (3) | |
$ | 20,670,000.00 | | |
| 0.0001476 | | |
$ | 3,050.89 | |
Total
Offering Amounts | |
$ | 20,670,000.00 | | |
| | | |
$ | 3,050.89 | |
Total
Fee Offsets | |
| | | |
| | | |
| — | |
Net
Fee Due | |
| | | |
| | | |
$ | 3,050.89 | |
(1) | Pursuant
to Rule 416 under the Securities Act of 1933, this Registration Statement also covers such
number of additional common shares that may become issuable under the Lineage Cell Therapeutics,
Inc. 2021 Equity Incentive Plan by reason of any stock split, stock dividend, recapitalization,
or any other similar transaction effected that results in an increase to the number of outstanding
common shares of the registrant. |
| |
(2) | Estimated
solely for the purpose of computing the registration fee in accordance with Rules 457(c)
and 457(h) under the Securities Act of 1933. |
| |
(3) | The
proposed maximum offering price is based on the average of the high and the low prices per
common share of the registrant as reported on the NYSE American as of a date (November 10,
2023) within five business days prior to the filing of this Registration Statement. |
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Jul 2023 to Jul 2024